HSD3B1 and metastatic neoplasm: We hypothesized that up-front pharmacologic blockade by use of AR antagonists alone with ADT would reverse the poor outcomes and survival associated with the adrenal-permissive HSD3B1 allele in patients with LV metastatic disease (Figure 1B).